Following completion of a capital increase in March 2021 to raise the necessary funds, momentum has . Oral Platform Presentation: . Shield Therapeutics plc (AIM: STX) is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals that addresses patients' unmet medical needs, with an initial focus on addressing iron deficiency anaemia in adults with its approved product Feraccru/Accrufer. 03/03/2021 1:40pm UK Regulatory (RNS & others) Shield Therapeutics (LSE:STX) Historical Stock . We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various . In Europe, the drug is branded as Ferracru and marketed by partner Norgine. Shield Therapeutics PLC 03 March 2021 Shield Therapeutics plc ("Shield Therapeutics" or the "Company") Investor. Proactive Research has published a new note on Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) ahead of the launch of iron deficiency drug Accrufer in the US. America is the key thrust for the group as it looks to roll out its ferric maltol product, which is known as Accrufer in the States and Feraccru elsewhere. 6/21/2021. Follow. Open Orphan Investor Presentation March 2022 (Video) 7 April . America is . To access the presentation, please visit Shield's investor relations page . Shield Therapeutics : Half-year Report Business Insider . . Shield Therapeutics PLC Investor Presentation. The company has an established commercial relationship with Norgine for Europe and signed a licensing deal with ASK . DATE: Thursday, June 24 th TIME: 10.00 am ET Our regions. PLC News; FTSE 100; FTSE 250; Funds; Interviews. Discover. Shield Therapeutics - Investor Presentation. Shield Therapeutics - Second Price Monitoring Extn. Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer/Feraccru (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Date: 08 Apr 2021. Shield Therapeutics - Investor Presentation. Shield Therapeutics plc ('Shield' or the 'Group' or the 'Company') Feraccru/Accrufer publications. Investor presentation . Shield invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.comLONDON, June 21, 2021 (GLOBE NEWSWIRE) -- Shield Therapeutics PLC (STX.L), based in Newcastle-upon-Tyne, UK, focused on addressing iron deficiency with its lead product Feraccru/Accrufer (ferric maltol), today announced that . Shield Therapeutics yesterday issued a trading statement indicating that it recorded modest initial revenues of 1.5mln, comprising 0.1mln of net . 02/04/2021 07:11:43 Cookie Policy +44 (0) 203 8794 460 Free Membership Login. To be informed of all SHIELD THERAPEUTICS PLC's upcoming presentations, register at InvestorMeetCompany: https://www.investormeetcompany.com/shield-therapeut. For further details please click here or visit our events page. Type: PDF . on 23/2/22. Shield Therapeutics plc, announces that it will provide a live presentation on Tuesday 9 March 2021 at 4.00pm covering the recent 25m fundraise and Open Offer to raise up to 4.2m and the US market opportunity ahead. Investegate announcements from Shield Therapeutics, Investor Presentation . Investegate 100d. Shield Therapeutics PLC today announced that Greg Madison, Chief Executive Officer, will present live at LifeSciencesInvestorForum.com on June 24 th . Shield Therapeutics plc ('Shield' or the 'Group' or the 'Company') Investor presentations. on 25/2/22. on 25/2/22. SpringWorks Therapeutics (SWTX) Investor Presentation - Slideshow. SHIELD THERAPEUTICS PLC. CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday June 14, 2022 at 10:00 a.m. P.T./ 1:00 p.m. E.T. Shield Therapeutics plc US launch of Accrufer confirmed for July 1, 2021 London, UK, June 24, 2021: Shield. Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru (R)/Accrufer (R) (ferric maltol), a novel, stable, non-salt based oral. 08, 2022 1:42 PM ET SpringWorks Therapeutics, Inc. (SWTX) SA Transcripts. Shield Therapeutics - Investor Presentation. Type: PDF . The Company specializes in the development and commercialization of late-stage pharmaceuticals which address areas of unmet medical need. Shield Therapeutics - Investor Presentation. Shield Therapeutics : Investor Presentation . Shield Therapeutics plc (LON:STX) is a commercial-stage company delivering specialty products that address patients' unmet medical needs, with an initial focus on treating iron deficiency (ID). | June 1, 2022 . 02/21: Shield Provides Full Year Trading Update and Reports Progress on the Commercialization .. AQ. Just the facts for an informed decision. Support: 888-992-3836 | NewsWire | Home | Login / Register Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) announced an exclusive licence agreement with KYE Pharmaceuticals Inc. for the development and commercialisation of its iron deficiency treatment Accrufer/Feraccru (ferric maltol) in Canada. Investor presentation . Investor presentation. Register as an investor, to follow and meet shareholders or management, and make informed decisions. Shield has recently launched Accrufer in the US, targeting a market of at least 10 million iron deficiency patients Accrufer has a 90% gross margin and the potential to reach $300m-$400m sales revenue in the US Accrufer/Feraccru has patent protection until 2035 We currently publish thousands of quarterly . Shield Therapeutics - Price Monitoring Extension. Under the deal, KYE will be responsible for all costs, both clinical and regulatory, for securing marketing authorisation and commercialisation of Accrufer in . Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Investor Presentation London, UK - 25 February 2022: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on treating iron deficiency with its lead product Accrufer/Ferracru, announces that it will provide a live investor presentation on Thursday 3 March 2022 at 4.30pm (GMT). Register Investor SHIELD THERAPEUTICS PLC Investor Introduction 2015; Abbaspour et al. . Shield Therapeutics plc announces that it will provide a live investor presentation on .. AQ. Investegate 372d. Latest Company Presentation Commercial stage pharmaceutical company Shield Therapeutics announced positive results from the AEGIS-H2H clinical trial on Monday, which compared 'Feraccru' (ferric maltol) - a novel oral . Register as an Investor Be part of the institutional roadshow and access companies without the need to travel. Monitor; . Helping patients become people . Disclaimer These slides have been prepared by Shield Therapeutics plc (the "Company") solely for your information and for use at a presentation for the purpose of providing background information on the Company, its STX.L Shield Therapeutics Plc. Register Investor. 16 Nov 2021. 25 articles with Shield Therapeutics. Just the facts for an informed decision. Live, interactive management presentations. Shield Therapeutics PLC 15 January 2021 Shield Therapeutics plc ("Shield" or the "Group" or the. Investor presentation 13:35:02 21 Jun 2021 - SHIELD THERAPEUTICS PLC - News article - Regulatory News Service. on 23/2/22. Feraccru/Accrufer has been approved by the regulators in both Europe and the US. Feraccru/Accrufer has been approved by the regulators in both Europe and the US. SHIEF: Get the latest Shield Therapeutics stock price and detailed information including SHIEF news, historical charts and realtime prices. on 25/2/22. Shield Therapeutics : Investor presentation. Results for the Year Ended 31 December 2020 - Investor Presentation. Shield Therapeutics plc www.shieldtherapeutics.com Tim Watts, CEO +44 (0)20 7186 8500 Nominated Adviser and Joint Broker Peel Hunt LLP James Steel/Dr Christopher Golden +44 (0)20 7418 8900 Joint Broker finnCap Ltd Geoff Nash/Matt Radley/Alice Lane +44 (0)20 7220 0500 Financial PR & IR Advisor Walbrook PR +44 (0)20 7933 8780 or shield@walbrookpr . Shield Therapeutics plc (LON:STX) is a commercial-stage pharma company delivering specialty products that address patients' unmet medical needs, with an initial focus on iron deficiency (ID).Following the US launch of Accrufer in July 2021, the initial challenge was to greatly improve market awareness of its differentiating features as an oral ID drug. Shield invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.comLONDON, June 21, 2021 (GLOBE . London Stock Exchange. PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will be included at the 2022 MDA Clinical & Scientific Conference, being held March 13-16, 2022 in Nashville, TN and virtually. Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru/Accrufer (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru/Accrufer has been approved by the regulators in both Europe and the US. Shield Therapeutics - Price Monitoring Extension. Search for: Search Button Home; News. Shield Therapeutics plc (LON:STX) is a commercial-stage company delivering specialty products that address patients' unmet medical needs, with an initial focus on treating iron deficiency (ID). Investor Relations. Discover . Available to all investors regardless of the number of shares they own or where they live. SA Transcripts. Hardman/LSE Life Sciences Forum The Company's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for . SHIELD THERAPEUTICS PLC. The US commercialisation of Accrufer is key to unlocking value (the US iron market is a huge market at ~10 million patients per year and is the key value driver) and FDA approval in 2019 led to the broadest possible label . These slides have been prepared by Shield Therapeutics plc (the "Company") solely for your information and for use at a presentation for the purpose of providing background information on the Company, its business and the industry in which it operates. London, UK, 3 June 2020: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru /Accrufer (ferric maltol), notes the recent publication of two papers concerning Feraccru /Accrufer . *A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: Obtains access to the information in a personal capacity; IMC Presentation. About Shield. Shield invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.comLONDON, June 21, 2021 (GLOBE . Shield Therapeutics NewsMORE. Shield Therapeutics plc is a United Kingdom-based commercial stage specialty pharmaceutical company. Shield Therapeutics (STX) Full Year Trading Update: 04 Feb 2022: 7:00 am: RNS: Shield Therapeutics (STX) KOL Investor Event on Iron Deficiency: 07 Jan 2022: 7:00 am: RNS: Shield Therapeutics (STX) Investor Presentation: 05 Jan 2022: 7:00 am: RNS: Shield Therapeutics (STX) Licence Agreement in Canada for Accrufer 30 Dec 2021: 9:06 am: RNS . 3 weeks, 2 days ago. LONDON, June 21, 2021 (GLOBE NEWSWIRE) -- Shield Therapeutics PLC (STX.L), based in Newcastle-upon-Tyne, UK, focused on addressing iron deficiency with its lead product Feraccru /Accrufer . Shield Therapeutics plc (AIM: STX) is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals that addresses patients' unmet medical needs, with an initial focus on addressing iron deficiency anaemia in adults with its approved product Feraccru/Accrufer. Shield Therapeutics plc www.shieldtherapeutics.com Greg Madison, CEO +44 (0) 191 511 8500 Hans-Peter Rudolf, CFO Nominated Adviser and Joint Broker Peel Hunt LLP James Steel/Christopher Golden +44 (0)20 7418 8900 Joint Broker finnCap Ltd Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks +44 (0)20 7220 0500 Financial PR & IR Advisor Walbrook . This presentation is confidential and is being supplied to you solely for your information and may not be reproduced, re-distributed or passed on, directly or indirectly, to any other person or published in whole or in . Investor Presentation - Shield Therapeutics Investor Presentation 26 Sep 2019 Shield Therapeutics plc, announces that the Company will be hosting an investor presentation on Tuesday 12 November 2019. Chief Executive Officer, Greg Madison will present alongside Chief Financial Officer, Hans-Peter Rudolf and Chief Medical Officer, Dr Jos Menoyo to provide an update to investors following the recent trading statement. Bid---Ask. on 23/2/22. Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) said 2021 revenues will be in line with expectations at 1.5mln as it made the first sales of its breakthrough drug for iron deficiency. Back to news 28/04/2021 04:51:04 Cookie Policy +44 (0) 203 8794 460 Free Membership Login. 127.69K Follower s. Join our live investor presentation with Investor Meet Company on Thursday 3 March 2022 at 4.30pm (GMT). 2015; Abbaspour et al. Shield Therapeutics - Second Price Monitoring Extn. Shield Therapeutics : Investor presentation Business Insider 5 days ago. Shield Therapeutics plc (LON:STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients' unmet medical needs, with an initial focus on treating iron deficiency (ID). Proactive Research analyst Robin Davison presents his research on Shield Therapeutics after the firm issued a trading statement indicating that it recorded modest initial revenues of 1.5mln, comprising 0.1mln of net product sales from US commercial activities, 0.9mln of royalties from sales by Norgine in the EU and milestones of 0.5mln. . High-OPEN-VOL-MKT CAP-M. LOW-CLOSE-AVG VOL-SHARES IN . Source: Shield Therapeutics Investor Materials, 2017; MedScape; EMA; Stallmach et al. 2014; L.E.K . Shield Therapeutics plc is a United Kingdom-based commercial stage specialty pharmaceutical company. Load more. Jun. Shield invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.comLONDON, June 21, 2021 (GLOBE NEWSWIRE) -- Shield Therapeutics PLC (STX.L), based in Newcastle-upon-Tyne, UK, focused on addressing iron deficiency with its lead product Feraccru/Accrufer (ferric maltol), today announced that . . Unfollow. Shield Therapeutics - Second Price Monitoring Extn. Source: Shield Therapeutics Investor Materials, 2017; MedScape; EMA; Stallmach et al. This presentation is confidential and is being supplied to you solely for your information and may not be reproduced, re-distributed or passed on, directly or indirectly, to any other person or published in whole or in . Shield Therapeutics PLC ("Shield") to Webcast Live at Life Sciences Investor Forum June 24th . At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. Investegate announcements from Shield Therapeutics, Investor presentation . 2014; L.E.K . At an investor presentation last week, Shield disclosed that Accrufer is listed on formularies of four US healthcare providers Optimum, Express Scripts, 23rd August 2021 06:00. interactive management presentations. Free forex prices, toplists, indices and lots more. Shield Therapeutics - Second Price Monitoring Extn. Investor presentations - Shield Therapeutics Investor presentations 29 Aug 2019 Shield Therapeutics plc, announces that the Company will be presenting at the following investor forums, providing an opportunity for investors to hear about the progress being made by the Company. Shield Therapeutics : Results of 2021 Annual General Meeting. Interviews; Q & A; Request an Interview Shield Therapeutics - Price Monitoring Extension. Back to news London, UK, 28 May 2020: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru /Accrufer (ferric maltol), will be presenting at two investor presentations next month, providing an overview of the . Accrufer is an effective oral product to treat iron deficiency (anaemia), says Proactive analyst . . shield therapeutics plc www.shieldtherapeutics.com greg madison, ceo +44 (0) 191 511 8500 hans-peter rudolf, cfo nominated adviser and joint broker peel hunt llp james steel/christopher golden +44. Type: PDF . Shield Therapeutics : Investor Presentation. 23rd August 2021 07:56. Shield Therapeutics (STX) stock price, charts, trades & the US's most popular discussion forums. Investor presentations - Shield Therapeutics Investor presentations 23 Jan 2019 Shield Therapeutics plc, announces it will be presenting at two investor presentations this month. Monitor; . Shield Therapeutics - Investor Presentation. Shield Therapeutics plc | 3,051 followers on LinkedIn. Price Snapshot Last Trades. 3 weeks ago. . on 25/2/22. Investor Presentation Shares Magazine/AJ Bell webinar 20 January 2021 Page 1. Shield Therapeutics - Second Price Monitoring Extn. The Company's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Shield Therapeutics : Investor Presentation markets.businessinsider.com - March 4 at 12:52 PM 'We had the Cadillac': San Joaquin County looking to challenge Blue Shield . Shield Therapeutics - Investor presentation. Following completion of a capital increase in March 2021 to raise the necessary funds, momentum has . Shield Therapeutics plc (LON:STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients' unmet medical needs, with an initial focus on treating iron deficiency (ID). Feraccru/Accrufer has been approved by the regulators in both Europe and the US. 127.69K Follower s. Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. Shield Therapeutics - PDMR Transaction Notification. Shield Therapeutics : Total Voting Rights Update. Analyst Riccardo Lowi discusses Shield Therapeutics PLC's (LON:STX) lead asset Feraccru - a novel and highly differentiated iron formulation,. Investegate 352d. Investegate announcements from Shield Therapeutics, Investor presentation . on 24/2/22. CEO, Tim Watts will present and introduce Brian Groch, who will run the Company's US commercial operations. Shield Therapeutics - Price Monitoring Extension. London, UK, 15 January 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on . Shield Therapeutics plc (LON:STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients' unmet medical needs, with an initial focus on treating iron deficiency (ID). Shield Therapeutics - 2021 focus on Accrufer. Date: 29 Apr 2021. Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) said 2021 revenues will be in line with expectations at 1.5mln as it made the first sales of its breakthrough drug for iron deficiency. Accrufer has just been launched in the US by Shield, where the initial aim is to greatly improve market awareness of its differentiating characteristics as an oral ID drug. Start your journey here Discover the world's international exchange. Available to all investors regardless of the number of shares they own or where they live. . Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru /Accrufer (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield Therapeutics plc announces that it will provide a live investor presentation on Thursday 3 March 2022 at 4.30pm (GMT). For further information click here. Proactive Investor 1-2-1 Forum. Shield Therapeutics : Second Price Monitoring Extn. Investors in Shield Therapeutics (LON:STX) from five years ago are still down 78%, even after 32% gain this past week finance.yahoo.com - December 22 at 1:21 PM: . Investor Introduction . Shield Therapeutics (STX) successfully launched its key asset, Accrufer (oral ferric maltol for iron deficiency), in the US market on 1 July, in line with previous guidance. About Shield Therapeutics plc. Shield Therapeutics is a well-funded, high potential, commercial stage specialty-pharma company. Shield Therapeutics - Price Monitoring Extension. London, UK, 21 June 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru (R)/Accrufer (R) (ferric maltol), announces that Greg Madison, Chief Executive Officer, will present at the OTCQX Life Science Virtual Investor . London, UK, Sept19ember 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs and . About Shield Therapeutics plc. The Company specializes in the development and commercialization of late-stage pharmaceuticals which address areas of unmet medical need. Shield Therapeutics : Appointment of new Chief .